On the issue of neoadjuvant therapy in patients with renal cell carcinoma

In the era of targeted therapy, the researchers focused attention on the role of neoadjuvant targeted therapy in the treatment of patients with renal cell carcinoma. The advantages of neoadjuvant therapy in advanced RCC include: identification of patients with primary refractory tumors, tumor shrinkage, rapid onset of systemic therapy Sorafenib and sunitinib are now most tested and suitable for neoadjuvant targeted therapy.